Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-745 · 2 trials · 2 indications
Percent change in global cortical amyloid specific PET signal (BPND)
Number of patients meeting protocol pre-specified definition of response: \> 7% reduction in global cortical BPND
Cytokines: Of nine cytokines assessed, only CSF IL-8 quantifiable at all time points. And so, only IL-8 levels are being reported herein. The analysis was exploratory and no statistical analysis was performed.
| Arm | Type | Description |
|---|---|---|
| VX-745 dose 1 | EXPERIMENTAL | Active Group 1: VX-745 40 mg twice daily |
| VX-745 dose 2 | EXPERIMENTAL | Active Group 2: VX-745 125 mg twice daily |
| VX-745 dose level 1 | EXPERIMENTAL | Active Group 1: VX-745 dose level 1 twice daily |
| VX-745 dose level 2 | EXPERIMENTAL | Active Group 1: VX-745 dose level 2 twice daily |
| Name | Type | Description |
|---|---|---|
| VX-745 | DRUG | Orally-Active Selective P45 MAP Kinase inhibitor |
Inclusion Criteria: * Willing and able to provide informed consent * Diagnosis of mild cognitive impairment (MCI) due to probable AD or of mild AD * MMSE range: 20 to 28 * Evidence of amyloid pathology by amyloid PET scan * Participants may be taking medications for AD, provided that the dose of th...
Top 20 of 24 competitors
VX-745 is an investigational small molecule being studied for Alzheimer's Disease. It is a p38 MAP kinase inhibitor that has been evaluated in Phase 2 clinical trials for patients with mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease. The drug is not approved and remains in clinical development.
VX-745 targets p38 MAP kinase, an enzyme involved in inflammatory signaling pathways. By inhibiting this kinase, the drug is being investigated for its potential effects on Alzheimer's Disease, including its impact on amyloid plaque load in the brain.
VX-745 is being developed by CervoMed Inc., a biopharmaceutical company. CervoMed's stock is traded under the ticker symbol CRVO. The company is conducting clinical research on this investigational drug for Alzheimer's Disease.
VX-745 is in Phase 2 clinical development. It has completed two Phase 2 trials, with a total of 32 participants enrolled. The drug is investigational and has not been approved by regulatory authorities for any use.
VX-745 has completed two Phase 2 trials. NCT02423122 studied its effects on amyloid plaque load in Alzheimer's Disease and mild cognitive impairment in the Netherlands. NCT02423200 evaluated its clinical pharmacology in mild cognitive impairment due to Alzheimer's Disease or mild AD in the United States.
VX-745 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information. It is identified solely as VX-745 in the studies conducted by CervoMed Inc.